MIST Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.190

-0%

-0.230

-25.81%

-0.300

+50%

Estimates Revision

The market is revising No Change the revenue expectations for Milestone Pharmaceuticals Inc. (MIST) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 17.26%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-12.45%

In Past 3 Month

Stock Price

Go Up

+17.26%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast MIST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIST is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 2.285

Low

4.00

Averages

4.50

High

5.00

Current: 2.285

Low

4.00

Averages

4.50

High

5.00

Wells Fargo

Overweight

initiated

2025-09-11

Reason

Wells Fargo

Price Target

2025-09-11

initiated

Overweight

Reason

Wells Fargo initiated coverage of Milestone Pharmaceuticals with an Overweight rating and $4 price target. The company is developing Etripamil, a nasal administered, short-acting, calcium channel blocker for the treatment of paroxysmal supraventricular tachycardia, the analyst tells investors in a research note. The firm views Etripamil as "highly differentiated" versus the standard of care and sees the potential for it to emerge as one of the key drugs for acute treatment.

H.C. Wainwright

Brandon Folkes

initiated

2025-06-05

Reason

H.C. Wainwright

Brandon Folkes

Price Target

2025-06-05

initiated

Reason

H.C. Wainwright analyst Brandon Folkes assumed coverage of Milestone Pharmaceuticals with a Buy rating and $5 price target. Milestone is developing Cardamyst for the treatment of paroxysmal supraventricular tachycardia, the analyst tells investors in a research note. The firm sees a path to resubmission in 2025, and a 2026 approval. The company's current enterprise value of $75M, ascribes a lower probability of resolving the complete response letter than is warranted, contends H.C. Wainwright.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Maintains

$25 → $10

2025-04-01

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$25 → $10

2025-04-01

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$25

2025-03-28

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$25

2025-03-28

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$25

2025-03-17

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$25

2025-03-17

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$25

2025-02-28

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$25

2025-02-28

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Milestone Pharmaceuticals Inc (MIST.O) is -2.36, compared to its 5-year average forward P/E of -2.98. For a more detailed relative valuation and DCF analysis to assess Milestone Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.98

Current PE

-2.36

Overvalued PE

-1.54

Undervalued PE

-4.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.98

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-1.00

Undervalued EV/EBITDA

-2.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

46.46

Current PS

12.83

Overvalued PS

136.85

Undervalued PS

-43.93

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MIST News & Events

Events Timeline

No data

News

9.0

12-13NASDAQ.COM

PinnedMIST Achieves Landmark Approval: FDA Greenlights First Self-Administered Nasal Spray for PSVT

9.0

12-13NASDAQ.COM

PinnedFDA Grants Approval for Milestone Pharma's CARDAMYST, the First Self-Administered Therapy for PSVT

9.0

12-13Globenewswire

PinnedMilestone Pharmaceuticals Receives FDA Approval for CARDAMYST to Treat PSVT

People Also Watch

Frequently Asked Questions

What is Milestone Pharmaceuticals Inc (MIST) stock price today?

The current price of MIST is 2.285 USD — it has decreased -5.19 % in the last trading day.

What is Milestone Pharmaceuticals Inc (MIST)'s business?

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.

What is the price predicton of MIST Stock?

What is Milestone Pharmaceuticals Inc (MIST)'s revenue for the last quarter?

Milestone Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Milestone Pharmaceuticals Inc (MIST)'s earnings per share (EPS) for the last quarter?

Milestone Pharmaceuticals Inc. EPS for the last quarter amounts to -0.12 USD, decreased -14.29 % YoY.

What changes have occurred in the market's expectations for Milestone Pharmaceuticals Inc (MIST)'s fundamentals?

How many employees does Milestone Pharmaceuticals Inc (MIST). have?

Milestone Pharmaceuticals Inc (MIST) has 33 emplpoyees as of December 15 2025.

What is Milestone Pharmaceuticals Inc (MIST) market cap?

Today MIST has the market capitalization of 205.26M USD.